Gustavo Della Flora Nunes

Thank you very much!

Thank you very much, Wendy!

4. Myelin loss delayed neuronal responses to visual stimuli. Thyromimetic treatment recovered these responses when myelin levels were still below those of healthy controls. But, the level of regeneration needed is not a simple threshold, also likely depending on timing of repair

3. A new thyromimetic developed by Autobahn Therapeutics resolved endogenous remyelination deficits by improving oligodendrocyte gain in the first 1.5 weeks of treatment. In comparison, at the tested doses, clemastine had a smaller and protracted effect

2. The drive for remyelination is recent loss of oligodendrocytes, not a restoration of the original oligodendrocyte population. So, there may be un unknown factor released around the timing of oligodendrocyte loss to promote remyelination

We used longitudinal in vivo 2P imaging and Neuropixels recordings in the cuprizone model to gain insights into important aspects of remyelination:
1. Endogenous remyelination is insufficient when demyelination is too severe and occurs too quickly

Extremely happy to share our manuscript jointly authored by me and the amazing Lyndsay Osso! An awesome collaboration between the @ethanhugheslab.bsky.social , Dan Denman and Autobahn Therapeutics. www.nature.com/articles/s41...
🧵

Nice! Can you add me to the list?